In the third of a four-part Daily Xtra series, Nicolas Kazamia looks at the controversy surrounding PrEP. Is it too early to call this drug a game-changer? Or is too much caution costing lives?

In the third part of our series on pre-exposure prophylaxis (PrEP), Daily Xtra looks at the controversy surrounding the HIV prevention drug. While many people are heralding a new chapter in the fight against HIV, others say it’s much too early to claim victory.

In the above video, Nicolas Kazamia speaks with Robert Grant, a senior researcher at the Gladstone Institutes; Alan McCord, from Project Inform; HIV/AIDS prevention workers Tim Ryan and Steve Gibson, from Magnet, a sexual health clinic in San Francisco; and Dale Gluth, the San Francisco Bay area director of the AIDS Healthcare Foundation.

Check back to Daily Xtra for our comprehensive online coverage of PrEP. And follow the conversation on our Facebook page and on Twitter.

In the series

Part 1: Can a pill a day keep HIV away?